New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis

Bibliographic Details
Main Authors:	Cara Barber, MD, MPH, Eingun James Song, MD
Format:	Article
Language:	English
Published:	Elsevier 2022-07-01
Series:	JAAD Case Reports
Subjects:	drug-induced lupus risankizumab severe plaque psoriasis systemic lupus erythematous
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512622002545

Similar Items

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
by: Cara Barber, MD, MPH, et al.
Published: (2022-06-01)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
by: Annunziata Dattola, et al.
Published: (2021-10-01)

Biomarkers in biological fluids and their potential use as indicators of lupus nephritis in individuals with systemic lupus erythematous
by: Lisandro Pacheco-Lugo, et al.
Published: (2014-05-01)

New possibilities of systemic therapy of plaque psoriasis with the IL23p19 inhibitor risankizumab
by: O. V. Zhukova, et al.
Published: (2021-06-01)

Risankizumab in the treatment of psoriasis – literature review
by: Katarzyna Banaszczyk
Published: (2019-06-01)

Rapidly and successful improvement of nail psoriasis with risankizumab
by: Diego Orsini, et al.
Published: (2023-10-01)

What Have We Learnt About the Treatment of Juvenile-Onset Systemic Lupus Erythematous Since Development of the SHARE Recommendations 2012?
by: Kathy L. Gallagher, et al.
Published: (2022-04-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023-12-01)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018-11-01)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022-08-01)

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
by: Paolo Gisondi, et al.
Published: (2021-09-01)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023-03-01)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
by: Angelo Ruggiero, et al.
Published: (2022-05-01)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
by: Machado Á, et al.
Published: (2018-11-01)

A case of erythematous lesions over the face
by: Kamal Ahmed1, Hardeep Singh2, Sameera Amreen1, Iqbal Ahmed1
Published: (2013-08-01)

Correlations between Serum prohepcidin level disease activity in rheumatoid arthritis and systemic lupus erythematous
by: Sahar S Ganeb, et al.
Published: (2016-01-01)

Systemic lupus erythematous presenting as catatonia and its response to electroconvulie therapy
by: Arshad Hussain, et al.
Published: (2015-01-01)

Clinical Manifestations of Systemic Lupus Erythematous in Children at Dr. Hasan Sadikin General Hospital Bandung, Indonesia
by: Reni Ghrahani, et al.
Published: (2018-12-01)

Supervivencia en pacientes cubanos con lupus eritematoso sistémico: influencia de las características iniciales de la enfermedad Survival of Cuban patients with systemic erythematous lupus: influence of the initial characteristics of the disease
by: Miguel Estévez del Toro, et al.
Published: (2008-09-01)

Coronavirus disease-19 triggered systemic lupus erythematous: A novel entity
by: Yadvir Garg, et al.
Published: (2023-01-01)

Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
by: Mark Lebwohl, et al.
Published: (2022-05-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Blood levels of brain-derived neurotrophic factor (BDNF) in systemic lupus erythematous (SLE): a systematic review and meta-analysis
by: Parnian Shobeiri, et al.
Published: (2023-03-01)

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
by: Luciano Ibba, et al.
Published: (2023-06-01)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021-11-01)

Call for Vigilance – Red Flags in Systemic Lupus Erythematous
by: Badar Hasan, et al.
Published: (2017-07-01)

An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
by: Hidehisa Saeki, et al.
Published: (2022-01-01)

Risankizumab: Daily Practice Experience of High Need Patients
by: Alexandra M. G. Brunasso, et al.
Published: (2023-06-01)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
by: Lauren M. Fahmy, BS, et al.
Published: (2023-11-01)

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors
by: Nicole L. Bolick, et al.
Published: (2020-12-01)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
by: Gönülal M, et al.
Published: (2023-12-01)

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
by: Gracia-Cazaña T, et al.
Published: (2023-01-01)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
by: Al Muqrin AM, et al.
Published: (2022-10-01)

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

CYTOKINE PROFILE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: Maria Eduardovna Tsanyan, et al.
Published: (2013-12-01)

Prevalence of substance use disorders among patients with systemic lupus erythematous and major depressive disorder
by: Kevin J. Varghese, et al.
Published: (2023-12-01)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
by: Matteo Megna, et al.
Published: (2023-04-01)

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
by: Bruce Strober, et al.
Published: (2022-10-01)

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022-09-01)